WO1992014449A1 - Controlled release microparticulate delivery system for proteins - Google Patents

Controlled release microparticulate delivery system for proteins Download PDF

Info

Publication number
WO1992014449A1
WO1992014449A1 PCT/US1992/001351 US9201351W WO9214449A1 WO 1992014449 A1 WO1992014449 A1 WO 1992014449A1 US 9201351 W US9201351 W US 9201351W WO 9214449 A1 WO9214449 A1 WO 9214449A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
fatty acid
microparticle
anhydride
acid anhydride
Prior art date
Application number
PCT/US1992/001351
Other languages
French (fr)
Inventor
Manoj Maniar
Abraham J. Domb
Original Assignee
Nova Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Pharmaceutical Corporation filed Critical Nova Pharmaceutical Corporation
Publication of WO1992014449A1 publication Critical patent/WO1992014449A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention is in the area of bioerodible controlled release systems for the dehvery and administration of labile proteins and peptides.
  • biodegradable matrix systems for the delivery of drugs and therapeutically active agents has been well developed and demonstrated to be clinically useful.
  • a number of methods have been well established for the controlled release of low molecular weight compounds.
  • high molecular weight compounds such as biologically active proteins and peptides, has been difficult with the presently investigated hydrophilic or hydrophobic, non-polymeric or polymeric matrices.
  • Bioerodible polymeric matrices have shown promise in the development of improved delivery systems.
  • Several polymers have been used, including poly(lactides) and their copolymers with glycolic acid, poly(orthoesters), ethylene vinyl acetate and poly (anhydrides).
  • Ethylene vinyl acetate has worked well for the release of biologically active proteins, but is not practical because it is non-degradable.
  • Poly(lactide/co-glycolide) has not shown much promise because there is a considerable amount of aggregation and denaturation of the protein within the matrix.
  • Poly (anhydrides) and poly(orthoesters) release proteins or peptides, but the release rates and the duration of release obtained were not acceptable.
  • microparticulate controlled release delivery system for controlled delivery of biologically active proteins.
  • An example of a biologically active and useful protein that is most effective when delivered continuously over extended periods of time is growth hormone. Unfortunately, this protein frequently aggregates, denatures and loses activity, within the matrix or during the preparation of the delivery system, making it difficult to deliver on a continuous basis.
  • a controlled release polymer implant system that has been developed to deliver growth hormone is described in European Patent Application No. 86305431.8 which discloses a sustained release microcapsule that contains the protein or peptide, an organic base substance as a drug retaining substance, and wherein the microcapsule wall is made of a polymer.
  • This system has several drawbacks. For example, because the device is not biodegradable, the device must be removed after treatment. Furthermore, the polymer utilized to form the device is limited to those which do not bind to nor promote aggregation of the protein. This limitation in the choice of the polymer also limits the range, type and extent of release of active agent.
  • the device is also limited to subcutaneous implantation in animals since use in humans would require post treatment removal of the device.
  • the biologically active protein is dissolved in water or a suitable solvent, alone or in combination with stabilizing agents.
  • the solution is either lyophilized or spray dried to obtain a free flowing powder.
  • the powder is then sieved to obtain the desired average particle size.
  • the free flowing powder of the protein or the stabilized protein is then incorporated into a biodegradable matrix formed of fatty acid anhydride, fatty acid and/or a salt thereof.
  • Examples using growth hormone and bovine serum albumin demonstrate the release, stability, and controlled release properties for the fatty acid anhydride microparticular system.
  • Figure 1 is a graph of the cumulative % release of recombinant bovine somatotropin (rbST) from microparticles formed of palmitic anhydride (squares) and palmitic acid (triangles) over time (hours) at room temperature.
  • rbST recombinant bovine somatotropin
  • Figure 2 is a graph of the cumulative % release of rbST from microparticles formed of stearic acid (open circles) and stearic anhydride (dark circles) over time (hours) at room temperature.
  • Figure 3 is the cumulative % release of stabilized rbSt from microparticles formed of stearic anhydride over time (hours) at 37 °C, where the stabilizer is PolysorbateTM 80, high pH (squares); sucrose (triangles); PolysorbateTM 80, neutral pH (circles), and potassium carbonate (asterisks).
  • Figure 4 is the cumulative % release of bovine serum albumin (BSA) from lauric acid microparticles over time (hours) at room temperature.
  • BSA bovine serum albumin
  • Figure 5 is a graph of the serum somatotropin level in nanograms/ml in nonlactating heifers over time (days) after subcutaneous injection of Nova A (somatotropin in stearic anhydride with sodium sulfate stabilizer in Miglycol 812).
  • Figure 6 is a graph of the serum somatotropin level in nanograms/ml in nonlactating heifers over time (days) after subcutaneous injection of Nova B (somatotropin in stearic anhydride with sucrose stabilizer in Miglycol 812).
  • Controlled release compositions suitable for use in continuously delivering biologically active protein, such as growth hormone and bovine serum albumin, and having enhanced stability with little or no loss of activity are formed from fatty acid anhydrides microparticles.
  • biologically active protein such as growth hormone and bovine serum albumin
  • the biodegradable microparticulate controlled delivery system containing biologically active proteins is useful in a wide range of applications.
  • the controlled release system is useful for controlled and/or enhanced administration of bovine, porcine or human growth hormones to livestock for increased milk production in lactating females and increased growth in maturing animals, as well as administration of growth hormone in human patients. Proteins
  • bioerodible, biocompatible controlled release microparticulate injectable delivery systems wherein the protein is bovine somatotropic hormone (rbSt) and bovine serum albumin (BSA).
  • the growth hormone is representative of labile proteins which tend to aggregate and BSA is representative of high molecular weight proteins.
  • BSA bovine serum albumin
  • biologically active protein refers to any therapeutically or biologically active protein, protein fragment, peptide, or analog thereof, unless otherwise stated, including proteins, active protein fragments and peptides which are naturally occurring, recombinan ⁇ y engineered or synthetically produced and which may further undergo various modifications, such as additions to or deletions of amino acids or domains or by glycosylation.
  • the microparticulate carriers are composed of a relatively large amount of fatty acid anhydride monomers or dinners, fatty acid and/or salts thereof.
  • the fatty acid anhydrides include, but not limited to, stearic anhydride, lauric anhydride, and palmitic anhydride.
  • fatty acids include, but not limited to, alkane-carboxylic acid, for example lauric acid and/or the salts thereof.
  • the fatty acid anhydrides can be obtained from a variety of commercial sources, such as Aldrich Chemical Co.
  • Salts of fatty acids have hitherto been used only as a lubricant in an impact tabletting process, but they have never been used in the controlled delivery of biologically active proteins or peptides.
  • stearic acid has been used in controlled release preparations, but only for the preparation of granules intended for the oral solid dosage form.
  • a simple surfactant such as polysorbateTM 80 high pH is used both as a stabilizer, to hinder aggregation and to increase the thermal stability of the protein towards denaturation, and to modulate the release rate of the protein from the biodegradable microparticulate controlled dehvery system.
  • Other stabilizers include, but are not limited to, simple polysaccharides such as sucrose, deoxycholic acid, sodium sulfate, polysorbate 80 neutral pH, polyhydric alcohols, and potassium carbonate.
  • Other protein stabilizing agents are known to those skilled in the art. The most preferred agent is sucrose or sodium sulfate.
  • the stabilizer causes a substantial increase in the duration of release of the protein and a decrease in initial release rate, when compared to a polymeric matrix formed from a biodegradable polymer in the absence of stabilizer, which permits longer and more uniform therapeutic treatment, without aggregation of the protein.
  • the stabilizing agent has several other effects on the protein. It stabilizes and protects the protein from denaturation, degradation and aggregation, thereby enhancing in vivo activity and allowing longer treatment periods between the successive injections. Co- lyophilization or spray drying the solution of protein with the stabilizer also alters both the rate of release and duration of release of the growth hormone from the microparticulate matrix. Significant control of the release rate and the released biological activity is achieved by this combination of stabilizer, protein, and microparticulate carriers.
  • the preferred method of making a controlled release, bioerodible, biocompatible, microparticulate injectable delivery system for the controlled delivery of biologically active protein is as follows.
  • the biologically active protein is dissolved in an appropriate solvent, such as water.
  • the solution is then lyophilized or spray dried to obtain a free flowing powder.
  • Stabilized protein is obtained by co- lyophilizing or spray drying an aqueous solution of the growth hormone and the stabilizer.
  • the free flowing powder is further reduced in particle size by mild trituration in a mortar with pestle.
  • the powder is then sieved to obtain the desired particle size, ranging generally from 10 to 400 ⁇ , most preferably approximately 100 ⁇ for subcutaneous administration.
  • the protein powder is then melt mixed with the appropriate microparticulate carrier, such as fatty acid anhydride or fatty acid and/or salts thereof.
  • the fatty acid anhydride is selected based on the denaturation temperature of the protein to be delivered.
  • the resulting melt is solidified by cooling to room temperature and then powdered to the desired particle size, in the range of 100 to 500 ⁇ , using any of the particle size reducing equipment known to those skilled in the art.
  • the ratio of protein to fatty acid anhydride will be in the range of 1 % to 50%.
  • stabilizer it will generally be in the range from 5 to 100% of the amount of protein.
  • the powdered and sieved protein is suspended in a solution of the microparticulate carrier.
  • the suspension is spray dried to obtain the final product.
  • the spray dried mixture can be used as an injectable or could be compressed into a device of specific shape for use as an implantable delivery system.
  • the sieved powder can be dry mixed with the appropriate microparticulate carrier, at the desired loading ratio, and processed by microencapsulation or pressing into an implantable device.
  • the microparticulate product or the devices are preferably stored at -20°C under an inert atmosphere prior to use. Carriers for in vivo Administration
  • Prolonged in vivo activity can be achieved by selecting an appropriate vehicle for suspending and administering the microparticles.
  • the preferred vehicles are the vegetable and/or mineral oils, mono, di or triglycerides like miglyols, and/or any fats and waxes of natural or synthetic origin which are deemed suitable as biocompatible materials.
  • Example 1 Preparation of microparticles of stearic acid containing recombinant bovine somatotropin (rbSt) by melt mixing.
  • Microparticles of stearic acid were prepared by combining the spray dried rbSt (20 mg) with stearic acid (80 mg). Spray dried powdered rbSt was added to the stearic acid, which was pre-melted at 75°C. The melt dispersion was mixed thoroughly with a spatula and cast into a thin film. The thin film was then grounded into the particles of the desired average size, approximately 400 ⁇ .
  • Example 2 Preparation of microparticles of stearic anhydride containing rbSt by solvent method.
  • a 2% solution (4 ml) of stearic anhydride was prepared by dissolving the stearic anhydride in dichloromethane. Powdered rbSt (20 mg) was added to that solution and a uniform dispersion was obtained by vortexing the suspension. The suspension was cast as a thin film on a glass plate. The solvent was removed from the film using a stream of dry nitrogen gas. After removal of the solvent, particles of stearic anhydride embedded with rbSt were obtained. Residual solvent was completely removed by lyophilizing the particles.
  • Example 3 Preparation of microparticles of stearic anhydride containing rbSt by spray drying method.
  • Example 4 Preparation of microparticles of lauric acid containing bovine serum albumin (BSA) by melt mixing.
  • BSA bovine serum albumin
  • Microparticles of stearic acid were prepared by combining the spray dried BSA (20 mg) with lauric acid (80 mg). Spray dried powdered rbSt was added to the lauric acid, which was pre-melted at 45 °C. The melt dispersion was mixed thoroughly with a spatula and cast into a thin film. The thin film was then grounded into the particles of the desired average size, approximately 400 ⁇ .
  • Example 5 Preparation of stabilized rbSt.
  • the rbSt (150 mg) and stabilizer (37 mg) were dissolved in 200 ml of highly purified water. The solution is then transferred to a lyophilization flask. The solution is pre-frozen using a dry ice/acetone bath and lyophilized by standard methods. The resulting white crystalline powder is then reduced to the desired particle size by triturating it in a mortar with pestle.
  • the stabilizers evaluated were sucrose, potassium carbonate, sodium sulfate, deoxycholic acid and polysorbate 80. In case of polysorbate 80, the amount of rbSt and stabilizer were 100 mg and 5 mg, respectively.
  • Example 6 Preparation of microparticles of stearic anhydride containing stabilized rbSt.
  • Microparticles of stearic anhydride were prepared by combining the stabilized rbSt (75 mg), as described in Example 5, with stearic anhydride (300 mg) to obtain 20% w/w loading.
  • Stabilized rbSt was added to the stearic anhydride, which was pre-melted at 75 °C.
  • the melt dispersion was mixed thoroughly with a spatula and cast into a thin film. The thin film was then ground into particles of the desired average size.
  • the amount of stabilized rbSt and stearic anhydride were 50 mg and 200 mg, respectively.
  • Example 7 Preparation of microparticles of palmitic acid and palmitic anhydride containing rbSt.
  • Microparticles of palmitic acid and palmitic anhydride were prepared by combining spray dried rbSt (75 mg) with palmitic acid (225 mg) and palmitic anhydride (225 mg), respectively.
  • Spray dried powdered rbSt was added to the palmitic acid and palmitic anhydride, which were pre- melted at 65°C.
  • the melt dispersion was mixed thoroughly with a spatula and cast into a thin film. The thin film was then ground into the particles of the desired average size.
  • Example 8 Release of spray dried rbSt from the microparticles of palmitic acid and palmitic anhydride. Release studies were conducted with the microparticles (125 mg) of palmitic acid and palmitic anhydride containing spray dried rbSt prepared in example 7 by dispersing them in 20 ml of 0.1 M phosphate buffer, pH 7.4. The release study was conducted at 25 °C and the entire buffer was changed at appropriate time intervals. The amount of rbSt released was analyzed by size exclusion high pressure liquid chromatography. The release profile is shown in Figure 1.
  • Example 9 Release of spray dried rbSt from the microparticles of stearic acid and stearic anhydride. Release studies were conducted with the microparticles (125 mg) of stearic acid and stearic anhydride containing spray dried rbSt prepared in example 1 and 3 by dispersing them in 20 ml of 0.1 M phosphate buffer, pH 7.4. The release study was conducted at 25 °C and the entire buffer was changed at appropriate time intervals. The amount of rbSt released was analyzed by size exclusion chromatography. The release profile is shown in Figure 2.
  • Example 10 Release of stabilized rbSt from the microparticles of stearic anhydride.
  • Example 11 Release studies were conducted with the microparticles (125 mg) of stearic anhydride containing stabilized rbSt prepared as described in Example 6 by dispersing them in 20 ml of 0.1 M phosphate buffer, pH 7.4. The release study was conducted at 37 °C and the entire buffer was changed at appropriate time intervals. The amount of rbSt released was analyzed by size exclusion chromatography. The release profile is shown in Figure 3.
  • Example 11 Release of BSA from the microparticles of lauric acid.
  • Release studies were conducted with the microparticles (125 mg) of lauric acid containing spray dried BSA prepared as described in Example 4 by dispersing them in 20 ml of 0.1 M phosphate buffer, pH 7.4. The release study was conducted at 25 °C and the entire buffer was changed at appropriate time intervals. The amount of BSA released was analyzed by size exclusion chromatography. The release profile is shown in Figure 4.
  • Somatotropin was co-lyophilized separately with the stabilizers sodium sulfate and sucrose. The ratio of protein to stabilizer was 2:1.
  • Two samples of stearic anhydride (12.30 grams) were then melted in a mortar at 75 °C. To the stearic anhydride samples were added separately 5.25 grams of the two stabilized growth hormone mixtures, and the new mixtures mixed until they reached room temperature. The particles were triturated lightly and sieved through a 425 micron sieve. The microparticles that passed through the sieve were used for in vivo testing. The microparticles were suspended in Miglyol 812 (Huls Corporation) for subcutaneous injection in non-lactating Holstein heifers.
  • the formulations containing sodium sulfate and sucrose stabilized growth hormone in stearic anhydride were designated Nova A and Nova B, respectively.
  • Blood samples were taken at 0 and 12 hours on the day of injection, and then on days 1, 2, 3, 5, 7, 9, 11, 13, and 15 post-injection. Blood samples were also taken from three control (untreated) heifers at the same time intervals. Blood was allowed to clot at 23 °C for one hour, centrifuged at 1500 x g, and the serum decanted and stored at -20 °C for radioimmunoassay.
  • the serum somatotropin levels in nanograms/ml over time for Nova A and Nova B are illustrated in Figures 5 and 6, respectively.
  • the serum somatotropin level of non-injected control heifers remained relatively constant at 0.7 ng/ml. As illustrated in both Figures 5 and 6, the serum bovine somatotropin level in the treated heifers peaked at approximately 8-10 ng/ml approximately two days after injection, and remained above normal levels for at least nine days.

Abstract

An improved surface erodible controlled release composition and the manufacturing thereof, for the continuous administration of biologically active proteins or peptide fragments, is described. The biologically active protein is dissolved in water or a suitable solvent, alone or in combination with stabilizing agents. The solution is either lyophilized or spray dried to obtain a free flowing powder. The powder is then sieved to obtain the desired average particle size. The free flowing powder of the protein or the stabilized protein is then incorporated into a biodegradable matrix formed of fatty acid anhydride, fatty acid and/or a salt thereof. Examples using growth hormone and bovine serum albumin demonstrate enhanced release, stability and controlled release properties for the fatty acid anhydride microparticular system.

Description

CONTROLLED RELEASE MICROPARTICULATE DELIVERY SYSTEM FOR PROTEINS
Background of the Invention
The present invention is in the area of bioerodible controlled release systems for the dehvery and administration of labile proteins and peptides.
The concept of using biodegradable matrix systems for the delivery of drugs and therapeutically active agents has been well developed and demonstrated to be clinically useful. A number of methods have been well established for the controlled release of low molecular weight compounds. However, the delivery of high molecular weight compounds, such as biologically active proteins and peptides, has been difficult with the presently investigated hydrophilic or hydrophobic, non-polymeric or polymeric matrices.
Alternative methods or carriers for delivery which correct the deficiencies in these systems have been sought for years. Bioerodible polymeric matrices have shown promise in the development of improved delivery systems. Several polymers have been used, including poly(lactides) and their copolymers with glycolic acid, poly(orthoesters), ethylene vinyl acetate and poly (anhydrides). Ethylene vinyl acetate has worked well for the release of biologically active proteins, but is not practical because it is non-degradable. Poly(lactide/co-glycolide) has not shown much promise because there is a considerable amount of aggregation and denaturation of the protein within the matrix. Poly (anhydrides) and poly(orthoesters) release proteins or peptides, but the release rates and the duration of release obtained were not acceptable.
It would be particularly desirable to develop a microparticulate controlled release delivery system for controlled delivery of biologically active proteins. An example of a biologically active and useful protein that is most effective when delivered continuously over extended periods of time is growth hormone. Unfortunately, this protein frequently aggregates, denatures and loses activity, within the matrix or during the preparation of the delivery system, making it difficult to deliver on a continuous basis.
A controlled release polymer implant system that has been developed to deliver growth hormone is described in European Patent Application No. 86305431.8 which discloses a sustained release microcapsule that contains the protein or peptide, an organic base substance as a drug retaining substance, and wherein the microcapsule wall is made of a polymer. This system has several drawbacks. For example, because the device is not biodegradable, the device must be removed after treatment. Furthermore, the polymer utilized to form the device is limited to those which do not bind to nor promote aggregation of the protein. This limitation in the choice of the polymer also limits the range, type and extent of release of active agent. Polymers which might otherwise be desirable for reasons of release kinetics and duration, specifically polymers that are more hydrophilic or hydrophobic in nature, cannot be used due to interactions with, or adverse influence upon, the biologically active protein. The device is also limited to subcutaneous implantation in animals since use in humans would require post treatment removal of the device.
It is therefore an object of the present invention to provide a biodegradable controlled release microparticulate, injectable delivery system for controlled in vivo administration of proteins such as growth hormone.
It is another object of the present invention to provide a method of manufacturing a microparticulate injectable delivery system.
It is yet another object of the present invention to provide a method and means for stabilizing proteins such as growth hormone in biodegradable drug delivery systems, as well as a method of manufacturing a microparticulate injectable delivery system capable of delivering stabilized protein in the biologically active form. It is still a further object of the present invention to provide a method and means for modulating the rate of release of the parent or stabilized polypeptidic agents from the microparticulate drug dehvery system.
Summary of the Invention
An improved surface erodible controlled release composition and the manufacture thereof, for the continuous administration of biologically active proteins or peptide fragments, is described. The biologically active protein is dissolved in water or a suitable solvent, alone or in combination with stabilizing agents. The solution is either lyophilized or spray dried to obtain a free flowing powder. The powder is then sieved to obtain the desired average particle size. The free flowing powder of the protein or the stabilized protein is then incorporated into a biodegradable matrix formed of fatty acid anhydride, fatty acid and/or a salt thereof.
Examples using growth hormone and bovine serum albumin demonstrate the release, stability, and controlled release properties for the fatty acid anhydride microparticular system.
Brief Description of the Drawings
Figure 1 is a graph of the cumulative % release of recombinant bovine somatotropin (rbST) from microparticles formed of palmitic anhydride (squares) and palmitic acid (triangles) over time (hours) at room temperature.
Figure 2 is a graph of the cumulative % release of rbST from microparticles formed of stearic acid (open circles) and stearic anhydride (dark circles) over time (hours) at room temperature.
Figure 3 is the cumulative % release of stabilized rbSt from microparticles formed of stearic anhydride over time (hours) at 37 °C, where the stabilizer is Polysorbate™ 80, high pH (squares); sucrose (triangles); Polysorbate™ 80, neutral pH (circles), and potassium carbonate (asterisks). Figure 4 is the cumulative % release of bovine serum albumin (BSA) from lauric acid microparticles over time (hours) at room temperature.
Figure 5 is a graph of the serum somatotropin level in nanograms/ml in nonlactating heifers over time (days) after subcutaneous injection of Nova A (somatotropin in stearic anhydride with sodium sulfate stabilizer in Miglycol 812).
Figure 6 is a graph of the serum somatotropin level in nanograms/ml in nonlactating heifers over time (days) after subcutaneous injection of Nova B (somatotropin in stearic anhydride with sucrose stabilizer in Miglycol 812).
Detailed Description of the Invention
Controlled release compositions suitable for use in continuously delivering biologically active protein, such as growth hormone and bovine serum albumin, and having enhanced stability with little or no loss of activity, are formed from fatty acid anhydrides microparticles. The biodegradable microparticulate controlled delivery system containing biologically active proteins is useful in a wide range of applications. For example, the controlled release system is useful for controlled and/or enhanced administration of bovine, porcine or human growth hormones to livestock for increased milk production in lactating females and increased growth in maturing animals, as well as administration of growth hormone in human patients. Proteins
The system is described in detail using bioerodible, biocompatible controlled release microparticulate injectable delivery systems wherein the protein is bovine somatotropic hormone (rbSt) and bovine serum albumin (BSA). The growth hormone is representative of labile proteins which tend to aggregate and BSA is representative of high molecular weight proteins. However, any protein or peptide having therapeutic or biological activity can be used. The term "biologically active protein" refers to any therapeutically or biologically active protein, protein fragment, peptide, or analog thereof, unless otherwise stated, including proteins, active protein fragments and peptides which are naturally occurring, recombinanύy engineered or synthetically produced and which may further undergo various modifications, such as additions to or deletions of amino acids or domains or by glycosylation. Fatty Add Anhydrides
The microparticulate carriers are composed of a relatively large amount of fatty acid anhydride monomers or dinners, fatty acid and/or salts thereof. The fatty acid anhydrides include, but not limited to, stearic anhydride, lauric anhydride, and palmitic anhydride. Similarly, fatty acids include, but not limited to, alkane-carboxylic acid, for example lauric acid and/or the salts thereof. The fatty acid anhydrides can be obtained from a variety of commercial sources, such as Aldrich Chemical Co.
Salts of fatty acids have hitherto been used only as a lubricant in an impact tabletting process, but they have never been used in the controlled delivery of biologically active proteins or peptides. Similarly, stearic acid has been used in controlled release preparations, but only for the preparation of granules intended for the oral solid dosage form. Stabilizing Agents
In the preferred embodiment, a simple surfactant such as polysorbate™ 80 high pH is used both as a stabilizer, to hinder aggregation and to increase the thermal stability of the protein towards denaturation, and to modulate the release rate of the protein from the biodegradable microparticulate controlled dehvery system. Other stabilizers include, but are not limited to, simple polysaccharides such as sucrose, deoxycholic acid, sodium sulfate, polysorbate 80 neutral pH, polyhydric alcohols, and potassium carbonate. Other protein stabilizing agents are known to those skilled in the art. The most preferred agent is sucrose or sodium sulfate.
The stabilizer causes a substantial increase in the duration of release of the protein and a decrease in initial release rate, when compared to a polymeric matrix formed from a biodegradable polymer in the absence of stabilizer, which permits longer and more uniform therapeutic treatment, without aggregation of the protein. The stabilizing agent has several other effects on the protein. It stabilizes and protects the protein from denaturation, degradation and aggregation, thereby enhancing in vivo activity and allowing longer treatment periods between the successive injections. Co- lyophilization or spray drying the solution of protein with the stabilizer also alters both the rate of release and duration of release of the growth hormone from the microparticulate matrix. Significant control of the release rate and the released biological activity is achieved by this combination of stabilizer, protein, and microparticulate carriers. Method of Preparation
The preferred method of making a controlled release, bioerodible, biocompatible, microparticulate injectable delivery system for the controlled delivery of biologically active protein is as follows.
The biologically active protein is dissolved in an appropriate solvent, such as water. The solution is then lyophilized or spray dried to obtain a free flowing powder. Stabilized protein is obtained by co- lyophilizing or spray drying an aqueous solution of the growth hormone and the stabilizer. The free flowing powder is further reduced in particle size by mild trituration in a mortar with pestle. The powder is then sieved to obtain the desired particle size, ranging generally from 10 to 400 μ, most preferably approximately 100 μ for subcutaneous administration. The protein powder is then melt mixed with the appropriate microparticulate carrier, such as fatty acid anhydride or fatty acid and/or salts thereof. The fatty acid anhydride is selected based on the denaturation temperature of the protein to be delivered. The resulting melt is solidified by cooling to room temperature and then powdered to the desired particle size, in the range of 100 to 500 μ, using any of the particle size reducing equipment known to those skilled in the art. In general, the ratio of protein to fatty acid anhydride will be in the range of 1 % to 50%. When stabilizer is added, it will generally be in the range from 5 to 100% of the amount of protein.
Alternatively, the powdered and sieved protein is suspended in a solution of the microparticulate carrier. The suspension is spray dried to obtain the final product. The spray dried mixture can be used as an injectable or could be compressed into a device of specific shape for use as an implantable delivery system.
In yet another process, the sieved powder can be dry mixed with the appropriate microparticulate carrier, at the desired loading ratio, and processed by microencapsulation or pressing into an implantable device. The microparticulate product or the devices are preferably stored at -20°C under an inert atmosphere prior to use. Carriers for in vivo Administration
Prolonged in vivo activity can be achieved by selecting an appropriate vehicle for suspending and administering the microparticles. The preferred vehicles are the vegetable and/or mineral oils, mono, di or triglycerides like miglyols, and/or any fats and waxes of natural or synthetic origin which are deemed suitable as biocompatible materials.
The present invention is further described with reference to the following non-limiting examples demonstrating the preparation and characterization of microparticles with varying loading. Example 1: Preparation of microparticles of stearic acid containing recombinant bovine somatotropin (rbSt) by melt mixing.
Microparticles of stearic acid were prepared by combining the spray dried rbSt (20 mg) with stearic acid (80 mg). Spray dried powdered rbSt was added to the stearic acid, which was pre-melted at 75°C. The melt dispersion was mixed thoroughly with a spatula and cast into a thin film. The thin film was then grounded into the particles of the desired average size, approximately 400 μ.
Example 2: Preparation of microparticles of stearic anhydride containing rbSt by solvent method.
A 2% solution (4 ml) of stearic anhydride was prepared by dissolving the stearic anhydride in dichloromethane. Powdered rbSt (20 mg) was added to that solution and a uniform dispersion was obtained by vortexing the suspension. The suspension was cast as a thin film on a glass plate. The solvent was removed from the film using a stream of dry nitrogen gas. After removal of the solvent, particles of stearic anhydride embedded with rbSt were obtained. Residual solvent was completely removed by lyophilizing the particles.
The solvent free particles were powdered into a desired size range for in vivo application, approximately 400 μ. Example 3: Preparation of microparticles of stearic anhydride containing rbSt by spray drying method.
A suspension of rbSt in a solution of stearic anhydride was prepared as described in Example 2. The suspension was spray dried in a Buchi spray dryer to obtain microparticles embedded with rbSt. The average particle size of the microparticles was less than 250 microns. Example 4: Preparation of microparticles of lauric acid containing bovine serum albumin (BSA) by melt mixing.
Microparticles of stearic acid were prepared by combining the spray dried BSA (20 mg) with lauric acid (80 mg). Spray dried powdered rbSt was added to the lauric acid, which was pre-melted at 45 °C. The melt dispersion was mixed thoroughly with a spatula and cast into a thin film. The thin film was then grounded into the particles of the desired average size, approximately 400 μ. Example 5: Preparation of stabilized rbSt.
The rbSt (150 mg) and stabilizer (37 mg) were dissolved in 200 ml of highly purified water. The solution is then transferred to a lyophilization flask. The solution is pre-frozen using a dry ice/acetone bath and lyophilized by standard methods. The resulting white crystalline powder is then reduced to the desired particle size by triturating it in a mortar with pestle. The stabilizers evaluated were sucrose, potassium carbonate, sodium sulfate, deoxycholic acid and polysorbate 80. In case of polysorbate 80, the amount of rbSt and stabilizer were 100 mg and 5 mg, respectively. Example 6: Preparation of microparticles of stearic anhydride containing stabilized rbSt.
Microparticles of stearic anhydride were prepared by combining the stabilized rbSt (75 mg), as described in Example 5, with stearic anhydride (300 mg) to obtain 20% w/w loading. Stabilized rbSt was added to the stearic anhydride, which was pre-melted at 75 °C. The melt dispersion was mixed thoroughly with a spatula and cast into a thin film. The thin film was then ground into particles of the desired average size. When the rbst was stabilized with polysorbate 80, the amount of stabilized rbSt and stearic anhydride were 50 mg and 200 mg, respectively. Example 7: Preparation of microparticles of palmitic acid and palmitic anhydride containing rbSt. Microparticles of palmitic acid and palmitic anhydride were prepared by combining spray dried rbSt (75 mg) with palmitic acid (225 mg) and palmitic anhydride (225 mg), respectively. Spray dried powdered rbSt was added to the palmitic acid and palmitic anhydride, which were pre- melted at 65°C. The melt dispersion was mixed thoroughly with a spatula and cast into a thin film. The thin film was then ground into the particles of the desired average size.
Example 8: Release of spray dried rbSt from the microparticles of palmitic acid and palmitic anhydride. Release studies were conducted with the microparticles (125 mg) of palmitic acid and palmitic anhydride containing spray dried rbSt prepared in example 7 by dispersing them in 20 ml of 0.1 M phosphate buffer, pH 7.4. The release study was conducted at 25 °C and the entire buffer was changed at appropriate time intervals. The amount of rbSt released was analyzed by size exclusion high pressure liquid chromatography. The release profile is shown in Figure 1.
Example 9: Release of spray dried rbSt from the microparticles of stearic acid and stearic anhydride. Release studies were conducted with the microparticles (125 mg) of stearic acid and stearic anhydride containing spray dried rbSt prepared in example 1 and 3 by dispersing them in 20 ml of 0.1 M phosphate buffer, pH 7.4. The release study was conducted at 25 °C and the entire buffer was changed at appropriate time intervals. The amount of rbSt released was analyzed by size exclusion chromatography. The release profile is shown in Figure 2. Example 10: Release of stabilized rbSt from the microparticles of stearic anhydride.
Release studies were conducted with the microparticles (125 mg) of stearic anhydride containing stabilized rbSt prepared as described in Example 6 by dispersing them in 20 ml of 0.1 M phosphate buffer, pH 7.4. The release study was conducted at 37 °C and the entire buffer was changed at appropriate time intervals. The amount of rbSt released was analyzed by size exclusion chromatography. The release profile is shown in Figure 3. Example 11: Release of BSA from the microparticles of lauric acid.
Release studies were conducted with the microparticles (125 mg) of lauric acid containing spray dried BSA prepared as described in Example 4 by dispersing them in 20 ml of 0.1 M phosphate buffer, pH 7.4. The release study was conducted at 25 °C and the entire buffer was changed at appropriate time intervals. The amount of BSA released was analyzed by size exclusion chromatography. The release profile is shown in Figure 4.
The results in the above examples demonstrate that proteins can be incorporated into a microparticulate injectable system formed of fatty acids and fatty acid anhydrides for delivery of biologically active proteins, based on molecular weight determinations of the active monomer (versus the inactive dimer) and by radioimmunoassay. The combination of stabilizer and surface eroding matrix results in more complete release of the protein over an extended period of time. The highest yield and most linear results were obtained by the use of stearic anhydride and lauric acid. Example 12: In Yivo Release of Somatotropin from Stearic Anhydride in Heifers
Somatotropin was co-lyophilized separately with the stabilizers sodium sulfate and sucrose. The ratio of protein to stabilizer was 2:1. Two samples of stearic anhydride (12.30 grams) were then melted in a mortar at 75 °C. To the stearic anhydride samples were added separately 5.25 grams of the two stabilized growth hormone mixtures, and the new mixtures mixed until they reached room temperature. The particles were triturated lightly and sieved through a 425 micron sieve. The microparticles that passed through the sieve were used for in vivo testing. The microparticles were suspended in Miglyol 812 (Huls Corporation) for subcutaneous injection in non-lactating Holstein heifers. The formulations containing sodium sulfate and sucrose stabilized growth hormone in stearic anhydride were designated Nova A and Nova B, respectively. Blood samples were taken at 0 and 12 hours on the day of injection, and then on days 1, 2, 3, 5, 7, 9, 11, 13, and 15 post-injection. Blood samples were also taken from three control (untreated) heifers at the same time intervals. Blood was allowed to clot at 23 °C for one hour, centrifuged at 1500 x g, and the serum decanted and stored at -20 °C for radioimmunoassay. The serum somatotropin levels in nanograms/ml over time for Nova A and Nova B are illustrated in Figures 5 and 6, respectively. The serum somatotropin level of non-injected control heifers remained relatively constant at 0.7 ng/ml. As illustrated in both Figures 5 and 6, the serum bovine somatotropin level in the treated heifers peaked at approximately 8-10 ng/ml approximately two days after injection, and remained above normal levels for at least nine days.
Modifications and variations of the fatty acid microparticles for controlled release of proteins will be obvious to those skilled in the art, and are intended to come within the scope of the appended claims.

Claims

We claim:
1. A protein delivery microparticle comprising biologically active protein or peptide dispersed in fatty acid or fatty acid anhydride monomers or dimers.
2. The microparticle of claim 1 wherein the protein to fatty acid or fatty acid anhydride ratio is in the range of between 1:100 and 1:2, by weight of the protein to fatty acid anhydride.
3. The microparticle of claim 1 wherein the protein further comprises a stabilizer.
4. The microparticle of claim 3 wherein the ratio of stabilizer to protein is in the range of between 1:20 to 1:1, by weight of protein.
5. The microparticle of claim 1 wherein the protein is selected from the group of biologically active proteins, protein fragments, and peptides, which are naturally occurring, recombinantly engineered, or synthetically produced.
6. The microparticle of claim 5 wherein the protein is growth hormone.
7. The microparticle of claim 1 wherein the fatty acid or fatty acid anhydrides are selected from the group consisting of stearic anhydride, lauric anhydride, palmitic anhydride, and alkane-carboxylic acid, and salts thereof.
8. The microparticle of claim 1 having a size range of approximately 100 μ.
9. The microparticle of claim 1 further comprising a pharmaceutically acceptable carrier for administration to a human or an animal.
10. The microparticle of claim 9 wherein the carrier is selected from the group consisting of vegetable oils, mineral oils, mono, di or triglycerides, and fats and waxes of natural or synthetic origin.
11. A method for the preparation of a controlled delivery protein microparticle comprising incorporating a biologically active protein or peptide into a microparticle formed of fatty acid or fatty acid anhydride monomers or dimers by the steps of: providing a dry protein powder; mixing the protein with melted fatty acid or fatty acid anhydride at a temperature below which the protein denatures; and then solidifying the melted mixture.
12. The method of claim 11 wherein the protein is dried to form protein particles, then mixed with the fatty acid or fatty acid anhydride.
13. The method of claim 12 wherein the fatty acid or fatty acid anhydride is melted at a temperature below the denaturation temperature of the protein.
14. The method of claim 12 wherein the protein is physically mixed with the fatty acid or fatty acid anhydrides.
15. The method of claim 11 wherein the protein to fatty acid or fatty acid anhydride ratio is in the range of between 1:100 and 1:2, by weight of the protein to fatty acid anhydride.
16. The method of claim 11 farther comprising providing a stabilizer with the protein particles.
17. The method of claim 16 wherein the ratio of stabilizer to protein is in the range of between 1:20 to 1:1, by weight of protein.
18. The method of claim 11 further comprising suspending the protein microparticles in a pharmaceutically acceptable carrier for administration to a human or an animal selected from the group consisting of vegetable oils, mineral oils, mono, di or triglycerides, and fats and waxes of natural or synthetic origin.
19. The method of claim 11 wherein the protein is selected from the group of biologically active proteins, protein fragments, and peptides, which are naturally occurring, recombinantly engineered, or synthetically produced.
20. The method of claim 19 wherein the protein is growth hormone.
21. A method for the controlled dehvery of a protein comprising administering the protein containing microparticles of claim 1 to a human or an animal.
PCT/US1992/001351 1991-02-20 1992-02-20 Controlled release microparticulate delivery system for proteins WO1992014449A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65808991A 1991-02-20 1991-02-20
US658,089 1991-02-20

Publications (1)

Publication Number Publication Date
WO1992014449A1 true WO1992014449A1 (en) 1992-09-03

Family

ID=24639854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/001351 WO1992014449A1 (en) 1991-02-20 1992-02-20 Controlled release microparticulate delivery system for proteins

Country Status (3)

Country Link
US (1) US5482927A (en)
AU (1) AU1442592A (en)
WO (1) WO1992014449A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019020A1 (en) * 1993-02-23 1994-09-01 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
WO2000041682A1 (en) * 1999-01-18 2000-07-20 Lg Chemical Limited Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
EP1940751B1 (en) * 2005-10-27 2011-03-02 Wacker Chemie AG Dispersion powder containing fatty acid anhydrides
US8870810B2 (en) 1998-12-18 2014-10-28 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE220327T1 (en) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst PULMONARY RELEASE OF ACTIVE FRAGMENTS OF THE PARATHORMONE
US7448375B2 (en) * 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP0748213B1 (en) * 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
ATE299892T1 (en) * 1994-05-18 2005-08-15 Nektar Therapeutics METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
KR100210509B1 (en) * 1996-01-10 1999-07-15 성재갑 Composition for sustained release of animal growth hormone and method for preparation thereof
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
DK2280020T3 (en) * 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
JP2004515467A (en) * 2000-08-07 2004-05-27 ネクター セラピューティックス Inhalable, spray-dried, 4-helix bundle protein powder with minimal aggregates
ES2326209T3 (en) 2000-10-27 2009-10-05 Baxter Healthcare S.A. MICRO SPHERES PRODUCTION.
US6896906B2 (en) * 2000-12-21 2005-05-24 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030064033A1 (en) * 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
AU2002342241B2 (en) * 2001-11-01 2007-07-19 Novartis Ag Spray drying methods and compositions thereof
ES2364636T3 (en) 2001-12-19 2011-09-08 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
CA2471400A1 (en) * 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
JP4681231B2 (en) 2002-03-20 2011-05-11 マンカインド コーポレイション Inhaler
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
DE10234165B4 (en) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale A method of filling a trench formed in a substrate with an insulating material
MXPA05007154A (en) * 2002-12-30 2005-09-21 Nektar Therapeutics Prefilming atomizer.
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
WO2004060322A2 (en) * 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040151766A1 (en) * 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
CA2532837A1 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical particles by controlled phase separation
US20050048127A1 (en) * 2003-07-22 2005-03-03 Larry Brown Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
PT2319500E (en) * 2004-03-12 2013-01-23 Biodel Inc Rapid acting drug delivery compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CA2566075A1 (en) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
MXPA06012989A (en) * 2004-05-12 2007-06-12 Baxter Int Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes.
ATE409025T1 (en) 2004-05-12 2008-10-15 Baxter Int NUCLEIC ACID MICROBEDS, THEIR PRODUCTION AND DELIVERY
BRPI0514263B8 (en) 2004-08-20 2021-05-25 Mannkind Corp method for the synthesis of n-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine n-protected
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
US7638477B2 (en) * 2005-03-09 2009-12-29 Alberto-Culver Company Sustained-release fragrance delivery system
EP1885335A1 (en) * 2005-04-27 2008-02-13 BAXTER INTERNATIONAL INC. (a Delaware corporation) Surface-modified microparticles and methods of forming and using the same
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
EP1928423B1 (en) 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007098500A2 (en) 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CA2649109A1 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP2647712A3 (en) * 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
AU2007319577A1 (en) * 2006-10-06 2008-05-22 Baxter Healthcare S.A. Microencapsules containing surface-modified microparticles and methods of forming and using the same
EP2104489A2 (en) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
US8812071B2 (en) * 2007-03-07 2014-08-19 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
AU2008242842B2 (en) * 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
US8386027B2 (en) * 2007-04-27 2013-02-26 Echo Therapeutics, Inc. Skin permeation device for analyte sensing or transdermal drug delivery
MX2010007342A (en) * 2008-01-04 2010-08-26 Biodel Inc Insulin formulations for insulin release as a function of tissue glucose levels.
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2982550C (en) 2008-06-13 2020-08-25 Mannkind Corporation A dry powder inhaler and system for drug delivery
CN102065942B (en) 2008-06-20 2013-12-11 曼金德公司 An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
ES2943333T3 (en) 2009-06-12 2023-06-12 Mannkind Corp Diketopiperazine microparticles with defined surface areas
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
CN103826988B (en) 2011-04-01 2016-03-09 曼金德公司 For the blister package of pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US10226417B2 (en) * 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
JP6018640B2 (en) 2011-10-24 2016-11-02 マンカインド コーポレイション Analgesic composition effective for alleviating pain, and dry powder and dry powder drug delivery system comprising the composition
AU2012347926B2 (en) 2011-12-05 2018-03-15 Incept, Llc Medical organogel processes and compositions
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102391750B1 (en) 2013-03-15 2022-04-28 맨카인드 코포레이션 Microcrystalline diketopiperazine compositions and methods
CN105451716A (en) 2013-07-18 2016-03-30 曼金德公司 Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2018017610A1 (en) * 2016-07-18 2018-01-25 Tissuegen, Inc. Methods and compositions for maintaining the conformation and structural integrity of biomolecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257368A1 (en) * 1986-08-11 1988-03-02 American Cyanamid Company Compositions for parenteral administration and their use
EP0350246A2 (en) * 1988-07-05 1990-01-10 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925661A (en) * 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
KR950014440B1 (en) * 1986-08-11 1995-11-28 이노바타 바이오메드 리미티드 Phamacentical formulation comprising microcapsules
US4963368A (en) * 1988-04-18 1990-10-16 Nabisco Brands, Inc. Oxidoreductase enzyme stabilized highly unsaturated fatty acids and derivatives of such acids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257368A1 (en) * 1986-08-11 1988-03-02 American Cyanamid Company Compositions for parenteral administration and their use
EP0350246A2 (en) * 1988-07-05 1990-01-10 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF PHARMACEUTICS, Volume 54, issued 1989, P.Y. WANG, "Lipids as Excipient in Sustained Release Insulin Implants", pages 223-230. *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019020A1 (en) * 1993-02-23 1994-09-01 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5753219A (en) * 1993-02-23 1998-05-19 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5804557A (en) * 1993-02-23 1998-09-08 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
CN1108823C (en) * 1993-02-23 2003-05-21 基因技术股份有限公司 Excipient stabilization of polypeptides treated with organic solvents
US8870810B2 (en) 1998-12-18 2014-10-28 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
WO2000041682A1 (en) * 1999-01-18 2000-07-20 Lg Chemical Limited Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
AU751200B2 (en) * 1999-01-18 2002-08-08 Lg Life Sciences, Ltd. Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
EP2481401A1 (en) * 1999-01-18 2012-08-01 LG Life Sciences, Ltd. Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
EP1940751B1 (en) * 2005-10-27 2011-03-02 Wacker Chemie AG Dispersion powder containing fatty acid anhydrides

Also Published As

Publication number Publication date
AU1442592A (en) 1992-09-15
US5482927A (en) 1996-01-09

Similar Documents

Publication Publication Date Title
US5482927A (en) Controlled released microparticulate delivery system for proteins
US5122367A (en) Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone
US6465425B1 (en) Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
RU2098121C1 (en) Microcapsule for prolonged release of physiologically active peptide
US4675189A (en) Microencapsulation of water soluble active polypeptides
KR101231856B1 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
US6399103B1 (en) Method of producing a sustained-release preparation
US5654010A (en) Composition for sustained release of human growth hormone
CA2316159C (en) Prolonged release microcapsules
KR100236771B1 (en) Hyaluronate microparticles for sustained release of drug
EP0702959B1 (en) Cross-linked gelatin gel preparation containing basic fibroblast growth factor
AU710347B2 (en) Composition for sustained release of an agent
KR100442931B1 (en) Sustained release formulations of water soluble peptides and process for preparing same
US5081156A (en) Sustained-release preparation
JPH0713023B2 (en) Pharmaceutical composition for maintaining and controlling drug release over a long period of time
JPH10503198A (en) Controlled release of metal cation stabilized interferon
CZ390797A3 (en) Preparation with continuous release of human growth hormone
EP0138216B1 (en) Sustained-release ifn preparation for parenteral administration
KR100486028B1 (en) Protein-containing lipid implant for sustained delivery and its preparation method
JPS61236729A (en) Slow-releasing agent
KR100329336B1 (en) Hyaluronate microparticles for sustained release of a protein drug
NZ226723A (en) Injectable sustained release formulation comprising polypeptide dispersed in an absorbable biocompatible base
JPS6097918A (en) Long action pharmaceutical preparation of interferon
WO1996026716A1 (en) Elcatonin controlled release microsphere formulation for treatment of osteoporosis
JP2003531106A (en) Biodegradable microparticles containing novel erythropoietin stimulating protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA